CompletedPhase 4

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

China823 participantsStarted 2019-07-05

Plain-language summary

The only curative therapy for thalassemia major remains the replacement of the defective erythropoiesis by allogeneic hematopoietic stem cell transplantation(allo-HSCT). We conduct a prospective multicenter study to evaluate the efficacy of allo-HSCT in the treatment of thalassemia major.

Who can participate

Age range2 Years – 20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosed with thalassemia major.
✓. Indication of hematopoietic stem cell transplantation.
✓. A cardiac ejection fraction of \>50%; normal pulmonary function tests and pulmonary examination results; and normal kidney function.

Exclusion criteria

✕. Aspartate aminotransferase levels \> 4-fold the upper limit of the normal range for our institution's lab criteria;
✕. Uncontrolled bacterial, viral or fungal infections;
✕. Any other restriction for transplantation.

What they're measuring

Overall survival

Timeframe: 2 years

Thalassemia-free survival

Timeframe: 2 years

Trial details

NCT IDNCT04009525

SponsorFirst Affiliated Hospital of Guangxi Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-31

View on ClinicalTrials.gov More Thalassemia Major trials